Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma

Published:2007-04 Issue:4 Volume:35 Page:534-540
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Shimoni Avichai,Zwas S. Tzila,Oksman Yakov,Hardan Izhar,Shem-Tov Noga,Yerushalmi Ronit,Avigdor Abraham,Ben-Bassat Isaac,Nagler Arnon

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference24 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

2. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma;Philip;N Engl J Med,1987

3. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury;Shipp;J Clin Oncol,1999

4. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry;Vose;J Clin Oncol,2001

5. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioligand Therapy in Lymphoma;PET Clinics;2024-10

2. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma;Bone Marrow Transplantation;2023-06-30

3. Transplantation;Clinical Immunology;2023

4. Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?;Blood Reviews;2022-03

5. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels;Cancers;2021-06-06